Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized and Double-Blind Study to Assess the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab in Subjects With Advanced Nonsquamous NSCLC

NCT04416035 is registered in ClinicalTrials.gov with Zhejiang Teruisi Pharmaceutical Inc. as lead sponsor.

NCT NCT04416035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04416035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized and Double-Blind Study to Assess the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab in Subjects With Advanced Nonsquamous NSCLC
Lead sponsor
Zhejiang Teruisi Pharmaceutical Inc.
Phase
Phase 3
Overall status
Unknown status
Start date
August 17, 2020
Completion date
November 10, 2021
Enrollment
608 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-squamous non-small-cell lung cancer